Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > 4 mysterious generics??? Alan shows openness....JMO
View:
Post by happyretirement on Mar 22, 2017 10:18am

4 mysterious generics??? Alan shows openness....JMO

"earnout payment on the 4 mysterious generics they bought in July 2016 that "they can't talk about"  (these drugs will be what I anticipate will be the 3rd CMA investigation)"

"These products include Sodium Feredetate oral solution for the treatment of anemia, Trazadone oral solution for the treatment of depression, as well as two additional pipeline products".

On June 1, 2016, the Corporation announced that it had completed the acquisition of the global rights to four generic products through certain of its wholly-owned subsidiaries.

These products include Sodium Feredetate oral solution for the treatment of
anemia, Trazadone oral solution for the treatment of depression and antihistamine Alimemazine oral solution and tablets.

The
Corporation paid £ 21 for the acquisition with cash on hand. In addition, during the first quarter of 2017, the Corporation made £ 7 million in earn-out payments, as certain performance and supply targets were achieved.


 
Comment by GenericAdvocate on Mar 22, 2017 10:35am
happyretirement,  Latti may have something here as billy kenber wrote about Tazadone in this article https://www.thetimes.co.uk/article/duplicate-permits-let-manufacturers-keep-their-dominance-fsrkp3lnq https://www.thetimes.co.uk/article/duplicate-permits-let-manufacturers-keep-their-dominance-fsrkp3lnq You need a subscription to read the article but it said that Concordia bought a ...more  
Comment by happyretirement on Mar 22, 2017 11:31am
Interesting responses since most of Billy's inquiries lack responses....Dec. 24th date should mean contact with the NEW Concordia CEO... "Mr Sharma said that his licence for trazodone oral solution had a longer shelf life than AMCo’s existing one." "A spokeswoman for Concordia International, the new name for AMCo, said it complied with all applicable laws and took ...more  
Comment by GenericAdvocate on Mar 22, 2017 11:44am
happyretirement, Since you appear to follow their drugs, what are the brand names of the other three drugs they purchased?   See if you can find a cut and paste for us ...  maybe billy kenber can look into those as well.  And btw, the spokesperson's comments from Concordia are LAME and about the same time they had a job up on their website looking for legal counsel.  Many ...more  
Comment by happyretirement on Mar 22, 2017 11:56am
Maybe you mean Secretary if Francesco gave the wrong response to Billy... Concordia Healthcare's (CXRX) Q3 2016 Results - Earnings Call Transcript Francesco Tallarico - Chief Legal Officer and Secretary   Concordia International's (CXRX) CEO Allan Oberman Q4 2016 Results - Earnings Call Transcript Francesco Tallarico - Chief Legal Officer
Comment by BaytexBull on Mar 22, 2017 12:07pm
So he can't lie?   Thompson was a lawyer too, no?  I think he lied.   What point are you trying to make..  The poster asked for the branded drugs they bought and you are doing a cut and paste of people's titles.  When a company doesn't tell you the names of the drugs they buy and who they bought them from there is something that smells fishy.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities